Monday, 13th September

15:20 *Design, synthesis and evaluation of pyrazolo[3,4-d]pyrimidine kinase inhibitors for glioblastoma*

**Daniel Baillache**, CRUK Edinburgh Centre, University of Edinburgh, UK P04

15:22 *The next generation of covalent fragments: sulfur(VI) fluoride warheads for ligandability assessments and hit identification*

**Arron Aatkar**, University of Strathclyde / GlaxoSmithKline, UK P01

15:24 *Fragment library screening by Grating Coupling Interferometry (GCI) and benefits over Surface Plasmon Resonance (SPR)*

**Ray Boffey**, Domainex Ltd, UK P05

15:26 *Biological evaluation of carnosine analogues*

**Klaudia Chmielewska**, Gdansk University of Technology, Poland P06

15:28 *Glucuronide metabolites, why bother?*

**Liam Evans**, Hypha Discovery Limited, UK P07

15:30 In situ *click chemistry applied to bunyavirales: from conventional drug design to enzymes assembling their own inhibitors*

**Laura Garlatti**, AFMB CNRS, France P08

15:32 *A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis*

**Daniel Harris**, University of Glasgow, UKP10

15:34 *Exploiting the biophysical sweet spot in fragment-based drug discovery*

**Thomas Pesnot**, Concept Life Sciences, UK P18

15:36 *Characterisation of pharmaceutical formulations using Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS)*

**Niamh O'Mahoney**, University College Cork, Ireland P15

15:38 *Metabolites profiling, in vitro, in vivo, computational pharmacokinetics and biological predictions of aloe perryi resins methanolic extract*

**Khawla Kahtani**, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia P30

15.40 End

Tuesday, 14th September

14:35 *Kinetic evaluation of sulfur(VI) fluoride reactive functionalities to enable the rapid development of therapeutics*

**Katharine Gilbert**, University of Strathclyde / GlaxoSmithKline, UK P09

14:37 *Exploiting automated R group core and table generation From matched molecular pair data to accelerate SARS-CoV2 therapeutic discovery*

**Lauren Reid**, MedChemica Ltd, UK P20

14:39 *Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)*

**Wolfgang Schmidt**, Charles River Laboratories, UK P22

14:41 *Phenothiazine based small molecule as nanomolar 20S proteasome activator*

**Sophia Staerz**, Michigan State University, USA P23

14:43 *Accelerating lead optimization with AI-assisted generative design and scaffold hopping*

**Istvan Szabo**, ChemPass Ltd, Hungary P24

14:45 *High-throughput synthesis of PhotoAffinity Bits (PhABits) to study protein-ligand binding*

**Ross Thomas**, University of Strathclyde / GlaxoSmithKline, UK P25

14:47 In vitro *anticancer activity of urease mimetic Cobalt(III) complexes on A549- lung cancer cells*

**Bhawna Uprety**, University of Johannesburg, South Africa P27

14:49 *Development of a new native mass spectrometry platform for identifying protein-protein interaction inhibitors*

**Clinton Veale**, University of KwaZulu-Natal, South Africa P28

14:51 *S6K1 inhibitors for fragile X syndrome and triple negative breast cancer*

**David Walker**, Sentinel Oncology Ltd, UK P29

14:53 End